Aria Neurosciences, Inc. (Aria) is an emerging biopharmaceutical company dedicated to developing and commercializing novel disease modifying therapies for Alzheimer’s disease (AD).
June 1, 2013 - Aria Neurosciences fills key leadership positions. Mark A. Findeis, Ph.D has joined as Vice President of Research and Marc Silver has joined as Vice President of Business Operations. Please see more details under Management Bios.
June 18, 2012 - Hamden, CT: NYU/Aria Neurosciences abstract "An APP Translation Modulator ARN2966 Reduces Aß Deposition and Prevents Memory Deficit in AD Transgenic Mice" has been accepted for a symposium oral presentation....
May 1, 2011 - HAMDEN, CT: Aria Neurosciences, Inc. signed a license agreement with NYU School of Medicine for the intellectual property (IP) associated with the pending U.S. provisional patent application....
I
I
I
I
I
